Raiffeisen Bank International AG Buys 687 Shares of Cigna Group $CI

Raiffeisen Bank International AG raised its stake in Cigna Group (NYSE:CI) by 4.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,526 shares of the health services provider’s stock after acquiring an additional 687 shares during the quarter. Raiffeisen Bank International AG’s holdings in Cigna Group were worth $5,222,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Price T Rowe Associates Inc. MD increased its holdings in shares of Cigna Group by 10.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,056,806 shares of the health services provider’s stock valued at $3,966,690,000 after purchasing an additional 1,094,327 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in Cigna Group by 1.1% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 11,778,472 shares of the health services provider’s stock worth $3,893,727,000 after buying an additional 123,479 shares in the last quarter. Dodge & Cox boosted its position in Cigna Group by 1.3% in the 1st quarter. Dodge & Cox now owns 8,889,733 shares of the health services provider’s stock valued at $2,924,722,000 after buying an additional 117,125 shares during the last quarter. GQG Partners LLC increased its stake in shares of Cigna Group by 21.5% in the 1st quarter. GQG Partners LLC now owns 4,886,674 shares of the health services provider’s stock valued at $1,607,716,000 after buying an additional 865,092 shares during the period. Finally, Valeo Financial Advisors LLC increased its stake in shares of Cigna Group by 86,071.1% in the 2nd quarter. Valeo Financial Advisors LLC now owns 3,475,282 shares of the health services provider’s stock valued at $1,148,859,000 after buying an additional 3,471,249 shares during the period. 86.99% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Cigna Group

In other Cigna Group news, CEO David Cordani bought 4,134 shares of the firm’s stock in a transaction on Monday, November 3rd. The stock was purchased at an average cost of $241.88 per share, with a total value of $999,931.92. Following the completion of the purchase, the chief executive officer owned 157,935 shares in the company, valued at approximately $38,201,317.80. The trade was a 2.69% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Brian C. Evanko sold 5,368 shares of the stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $300.00, for a total value of $1,610,400.00. Following the completion of the sale, the insider owned 51,182 shares of the company’s stock, valued at $15,354,600. This trade represents a 9.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.70% of the stock is owned by insiders.

Cigna Group Price Performance

Cigna Group stock opened at $270.84 on Tuesday. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $72.35 billion, a P/E ratio of 14.78, a PEG ratio of 0.88 and a beta of 0.44. The business has a 50-day moving average of $289.16 and a 200-day moving average of $300.40. Cigna Group has a 1 year low of $239.51 and a 1 year high of $350.00.

Cigna Group (NYSE:CI) last announced its quarterly earnings results on Thursday, October 30th. The health services provider reported $7.83 earnings per share for the quarter, beating analysts’ consensus estimates of $7.64 by $0.19. The business had revenue of $69.57 billion for the quarter, compared to the consensus estimate of $66.40 billion. Cigna Group had a net margin of 1.92% and a return on equity of 18.80%. Cigna Group’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period last year, the company posted $7.51 EPS. Cigna Group has set its FY 2025 guidance at 29.600- EPS. On average, equities analysts anticipate that Cigna Group will post 29.77 EPS for the current year.

Cigna Group Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 18th. Stockholders of record on Thursday, December 4th will be given a dividend of $1.51 per share. This represents a $6.04 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Thursday, December 4th. Cigna Group’s dividend payout ratio (DPR) is currently 26.64%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. JPMorgan Chase & Co. cut their price target on Cigna Group from $428.00 to $375.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 4th. Guggenheim dropped their price objective on Cigna Group from $350.00 to $309.00 in a report on Friday, October 31st. Wells Fargo & Company reduced their target price on shares of Cigna Group from $354.00 to $300.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 5th. Sanford C. Bernstein lowered their price target on shares of Cigna Group from $346.00 to $294.00 and set a “market perform” rating for the company in a research report on Wednesday, November 12th. Finally, Zacks Research downgraded shares of Cigna Group from a “hold” rating to a “strong sell” rating in a research note on Monday, November 3rd. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Cigna Group presently has an average rating of “Moderate Buy” and a consensus price target of $334.05.

Cigna Group Profile

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.